Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8952107 | 1.00 | CYP2C9 (1.00) | CYP2C9PTP4A1MIFALDH1A1TSHR | |
| SCHEMBL29924198 | 1.00 | CYP2C9 (1.00) | CYP2C9PTP4A1MIFALDH1A1TSHR | |
| SCHEMBL28619646 | 0.86 | CYP2C9 (0.75) | CYP2C9PTP4A1MIFALDH1A1MAPT | |
| SCHEMBL28620837 | 0.83 | CYP2C9 (0.71) | CYP2C9PTP4A1MIFALDH1A1TSHR | |
| SCHEMBL2755215 | 0.82 | CYP2C9 (0.69) | CYP2C9PTP4A1MIFALDH1A1TSHR | |
| SCHEMBL4961560 | 0.82 | CYP2C9 (0.69) | CYP2C9PTP4A1MIFALDH1A1TSHR | |
| SCHEMBL4906704 | 0.82 | CYP2C9 (0.69) | CYP2C9PTP4A1MIFALDH1A1TSHR | |
| SCHEMBL8559723 | 0.81 | CYP2C9 (0.68) | CYP2C9PTP4A1MIFALDH1A1TSHR | |
| SCHEMBL8559725 | 0.81 | CYP2C9 (0.68) | CYP2C9PTP4A1MIFALDH1A1TSHR | |
| SCHEMBL9869805 | 0.80 | CYP2C9 (0.66) | CYP2C9PTP4A1MIFALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376057-A1 | 2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS | IRCCS NEUROMED S.P.A. (IT) | 2024-11-14 | — | — | US | disclosed |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
| CN-112041320-B | Compound capable of being used as tumor inhibitor and preparation method and application thereof | 甘李药业股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-11639355-B2 | Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors | Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2023-05-02 | — | — | US | disclosed |
| US-11639355-B2 | Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors | Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2023-05-02 | — | — | US | disclosed |
| US-11339171-B2 | MDM2 inhibitors | GAN & LEE PHARMACEUTICALS (CN) | 2022-05-24 | — | — | US | disclosed |
| US-11339171-B2 | MDM2 inhibitors | GAN & LEE PHARMACEUTICALS (CN) | 2022-05-24 | — | — | US | disclosed |
| US-20210230164-A1 | IMIDAXOPYROLONE COMPOUND AND APPLICATION THEREOF | Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) | 2021-07-29 | — | — | US | disclosed |
| US-20210079007-A1 | MDM2 Inhibitors | GAN & LEE PHARMACEUTICALS (CN) | 2021-03-18 | — | — | US | disclosed |
| WO-2021047466-A1 | CRYSTAL FORM OF P53-MDM2 INHIBITOR AND PREPARATION METHOD THEREFOR | 罗欣药业(上海)有限公司 | 2021-03-18 | — | — | WO | disclosed |
| EP-2298770-A1 | Heterocyclic compounds as TrkA modulators | ChemBridge Corporation (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| WO-2007056155-A1 | HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-5514816-A | REACTION OF DIFLUOROBENZO-1,3-DIOXOLE WITH METAL COMPOUNDS FOR INSECTICIDES | CIBA-GEIGY CORPORATION (US) | 1996-05-07 | — | — | US | disclosed |
| US-5496848-A | Process for the preparation of substituted difluorobenzo-1,3-dioxoles | CIBA-GEIGY CORPORATION (US) | 1996-03-05 | — | — | US | disclosed |
| US-5493032-A | INSECTICIDES, MICROBIOCIDES | CIBA-GEIGY CORPORATION (US) | 1996-02-20 | — | — | US | disclosed |
| US-5420301-A | Process for the preparation of substituted difluorobenzo-1,3-dioxoles | CIBA-GEIGY CORPORATION (US) | 1995-05-30 | — | — | US | disclosed |
| US-5281718-A | Reacting in one pot reaction 2,2-difluorobenzodioxole with an organometal compound or metal to form 4-metallo-2,2-difluorobenzodioxole, reacting with unsaturated nitrile, then with isocyanide | CIBA-GEIGY CORPORATION (US) | 1994-01-25 | — | — | US | disclosed |
| US-5241099-A | PROCESS FOR THE PREPARATION OF AMINOMETHYLENE COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 1993-08-31 | — | — | US | disclosed |
| US-5194628-A | Reacting metallo-difluorobenzodioxole with unsaturated nitrile and then with sulfonylmethyl isocyanide | CIBA-GEIGY CORPORATION (US) | 1993-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230164-A1 | IMIDAXOPYROLONE COMPOUND AND APPLICATION THEREOF | TP53, MDM2, TP53BP1 | CYP2C9 1932/4885PTP4A1 255/4885MIF 777/4885 |
| US-11639355-B2 | Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors | TP53, MDM2, TP53BP1 | CYP2C9 2197/4885PTP4A1 261/4885MIF 461/4885 |
| US-11339171-B2 | MDM2 inhibitors | MDM2, MDM4, TP53 | CYP2C9 2572/4885PTP4A1 521/4885MIF 90/4885 |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | CYP2C9 4838/4885PTP4A1 3709/4885MIF 929/4885 |
| US-20210079007-A1 | MDM2 Inhibitors | MDM2, MDM4, TP53 | CYP2C9 2572/4885PTP4A1 521/4885MIF 90/4885 |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | CYP2C9 4015/4885PTP4A1 256/4885MIF 294/4885 |
| US-20240376057-A1 | 2,4-DIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TUMORS | PDK2, G6PD, PDK1 | CYP2C9 654/4885PTP4A1 2017/4885MIF 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.